• CoronaCoronavirus (COVID-19) Resources

    In an effort to support our members with the most updated information on COVID-19 we developed this resource page to easily access current CDC information and other resources to assist you professionally and personally.

    We will continue to update this page with more information as it becomes available and welcome your input as we navigate through this situation. As health care professionals it is our job to educate our patients and families on prevention and the what to do if someone is symptomatic.

    View resources


  • Clinical Care OptionsNew for GAPNA members: Clinical Care Options

    GAPNA has partnered with a Clinical Care Options to offer an ongoing series of free CNE programs available to GAPNA members. "Diagnosis, Classification and Treatment of Heart Failure in Older Adults" is the latest program offered.

    In this interactive Webcast, expert faculty review the challenges of managing older adults with HF, including diagnosis, staging, and developing individualized management plans.

    Find out about it!

  • GAPNA 2020 National President Deborah Dunn, EdD, MSN, GNP-BC, ACNS-BC, GS-C interviews Dr. Ron Billano Ordona, DNP, FNP-BC about providing home-based primary care during COVID 19.

    "Facing Forward: Providing Home-based Primary Care during COVID 19"

    View the Video

Most Nursing Home Residents with Advanced Dementia Get Medications With Questionable Benefits and Substantial Costs

More than half of nursing home residents with advanced dementia continue to receive medications that may not help them, but incur substantial financial cost.

An analysis of more than 5,400 residents at 460 facilities (using 2009-2010 data) found nearly 54% of residents received at least one medication of questionable benefit.

The average 90-day expenditure for medications with questionable benefits was $816.

This accounts for 35.2% of the total average 90-day medication costs for residents with advanced dementia who were prescribed common medications with questionable benefits.

To learn more, see Tjia et al. (2014). Use of medications of questionable benefit in advanced dementia. JAMA Internal Medicine, 174(11), 1763-1771.

Related Topic 1: 

GAPNA Newsletter Issue: